Key facts
- BioWave’s last known valuation is $15.8M (Jan 2016).
- It has raised $7.5M across 2 recorded rounds; the latest was Seed Round ($1.3M) in Dec 2018.
- Notable investors include Connecticut Innovations, NorthStar Pain Management.
- BioWave has filed 3 Form Ds with the SEC since 2016, most recently Dec 2019 ($1.3M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for BioWave
Funding rounds
2 roundsAbout BioWave
Developer of neuromodulation therapy medical devices designed to provide pain relief. The company's devices specialize in the treatment of chronic, acute, and postoperative musculoskeletal pains, enabling patients to alleviate pain through effective neurostimulation services.
- Sector
- Healthcare
- HQ
- Westport, CT, United States
- Founded
- 2000
- Employees
- 86
- Website
- biowave.com/
- Ownership
- Privately Held (backing)
BioWave doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioWave shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioWave in its N-PORT filings yet. We sweep new filings monthly.